Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.86 |
| ▸ | ATM | Q13315 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 4/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16226380 | 0.83 | ALDH1A1 (0.81) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL16226486 | 0.82 | KMT2A (0.62) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL16226408 | 0.82 | KMT2A (0.62) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL16227069 | 0.81 | KMT2A (0.61) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL9720696 | 0.81 | MPO (0.69) | KMT2AATMMEN1OPRM1OPRD1 | |
| SCHEMBL14983599 | 0.81 | ALDH1A1 (0.62) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL20804484 | 0.78 | KMT2A (0.57) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL16226719 | 0.78 | ALDH1A1 (0.68) | KMT2AATMMEN1ALDH1A1CYP2A13 | |
| SCHEMBL7311276 | 0.78 | ATM (0.84) | KMT2AATMMEN1OPRM1OPRD1 | |
| SCHEMBL16226852 | 0.78 | MEN1 (0.86) | KMT2AATMMEN1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | KMT2A 2536/4885ATM 1835/4885MEN1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.